<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025593</url>
  </required_header>
  <id_info>
    <org_study_id>Guidance-01</org_study_id>
    <nct_id>NCT04025593</nct_id>
  </id_info>
  <brief_title>Biomarker Guided Treatment in DLBCL</brief_title>
  <official_title>A Randomized, Phase 2 Study of Biomarker Guided Treatment in DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the strategy of biomarker guided treatment in diffuse large B
      cell lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response rate</measure>
    <time_frame>21 days after 6 cycles of treatment (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>21 days after 6 cycles of treatment (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>RCHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RCHOPX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750mg/m2 day 1</description>
    <arm_group_label>RCHOP</arm_group_label>
    <arm_group_label>RCHOPX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375mg/m2 day 0</description>
    <arm_group_label>RCHOP</arm_group_label>
    <arm_group_label>RCHOPX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50mg/m2 day 1</description>
    <arm_group_label>RCHOP</arm_group_label>
    <arm_group_label>RCHOPX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4mg/m2, max 2mg day 1</description>
    <arm_group_label>RCHOP</arm_group_label>
    <arm_group_label>RCHOPX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>60mg/m2, max 100mg day 1-5</description>
    <arm_group_label>RCHOP</arm_group_label>
    <arm_group_label>RCHOPX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>560mg/day qd</description>
    <arm_group_label>RCHOPX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>25mg day1-10</description>
    <arm_group_label>RCHOPX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chidamide</intervention_name>
    <description>20mg day 1,4,8,11</description>
    <arm_group_label>RCHOPX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>decitabine</intervention_name>
    <description>decitabine 10mg/m2 day-5 to day-1</description>
    <arm_group_label>RCHOPX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed diffuse large B-cell lymphoma, CD20 positive

          -  ECOG 0,1,2

          -  Life expectancy&gt;6 months

          -  Informed consented

          -  IPI&gt;1

        Exclusion Criteria:

          -  Chemotherapy before

          -  Stem cell transplantation before

          -  History of malignancy except for basal cell or squamous cell carcinoma of the skin or
             carcinoma in situ of the cervix

          -  Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious
             disease

          -  Primary CNS lymphoma

          -  LVEFâ‰¤50%

          -  Lab at enrollment (Unless caused by lymphoma) Neutrophile&lt;1.5*10^9/L
             Platelet&lt;75*10^9/L ALT or AST &gt;2*ULN,AKP or bilirubin &gt;1.5*ULN Creatinine&gt;1.5*ULN
             Other uncontrollable medical condition that may that may interfere the participation
             of the study Not able to comply to the protocol for mental or other unknown reasons
             Pregnant or lactation HIV infection If HbsAg positive, should check HBV DNA, DNA
             positive patients cannot be enrolled. If HBsAg negative but HBcAb positive (whatever
             HBsAb status), should check HBV DNA,DNA positive patients cannot be enrolled.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>WL Z, MD PhD</last_name>
    <phone>64370045</phone>
    <phone_ext>610707</phone_ext>
    <email>zhao.weili@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pp X, MD, PhD</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>610707</phone_ext>
      <email>xpproc@msn.com</email>
    </contact>
    <investigator>
      <last_name>WL Z, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>PP X, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>Deputy director of hematology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

